NSAIDs may protect against age-related brain atrophy

Frontiers in Aging Neuroscience

Volumn 2, Issue SEP, 2010, Pages

  Bendlin, Barbara B ^a,b   Newman, Lisa M ^a,b   Ries, Michele L ^a,b   Puglielli, Luigi ^a,b   Carlsson, Cynthia M ^a,b   Sager, Mark A ^a,b   Rowley, Howard A ^b   Gallagher, Catherine L ^a,b   Willette, Auriel A ^b,c   Alexander, Andrew L ^b,d   Asthana, Sanjay ^a,b   Johnson, Sterling C ^a,b  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Aging; Alzheimer's disease; NSAIDs; Risk factors; Volumetric MRI

Indexed keywords

EID: 84859110180     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2010.00035     Document Type: Article

References (62)

1. Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., and Thal, L. J. (2003). Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289, 2819-2826.
2. Arriagada, P. V., Marzloff, K., and Hyman, B. T. (1992). Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 42, 1681-1688.
3. Arvanitakis, Z., Grodstein, F., Bienias, J. L., Schneider, J. A., Wilson, R. S., Kelly, J. F., Evans, D. A., and Bennett, D. A. (2008). Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 70, 2219-2225.
4. Banati, R. B., Gehrmann, J., Schubert, P., and Kreutzberg, G. W. (1993). Cytotoxicity of microglia. Glia 7, 111-118.
5. Bendlin, B. B., Ries, M. L., Canu, E., Sodhi, A., Lazar, M., Alexander, A. L., Carlsson, C. M., Sager, M. A., Asthana, S., and Johnson, S. C. (In press). White matter is altered with parental family history of Alzheimer's disease. Alzheimer's Dementia, doi:10.1016/j.jalz.2009.11.003.
6. Blasko, I., Apochal, A., Boeck, G., Hartmann, T., Grubeck-Loebenstein, B., and Ransmayr, G. (2001). Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. Neurobiol. Dis. 8, 1094-1101.
7. Braak, H., and Braak, E. (1997). Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351-357.
8. Burggren, A. C., Zeineh, M. M., Ekstrom, A. D., Braskie, M. N., Thompson, P. M., Small, G. W., and Bookheimer, S. Y. (2008). Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. Neuroimage 41, 1177-1183.
9. Canadian study of health and aging: study methods and prevalence of dementia (1994). CMAJ 150, 899-913.
10. Chakrabarty, P., Jansen-West, K., Beccard, A., Ceballos-Diaz, C., Levites, Y., Verbeeck, C., Zubair, A. C., Dickson, D., Golde, T. E., and Das, P. (2009). Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 24, 548-559.
11. de Jong, D., Jansen, R., Hoefnagels, W., Jellesma-Eggenkamp, M., Verbeek, M., Borm, G., and Kremer, B. (2008). No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS One 3, e1475. doi:10.1371/journal.pone.0001475.
12. de Leon, M. J., George, A. E., Stylopoulos, L. A., Smith, G., and Miller, D. C. (1989). Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet 2, 672-673.
13. DeKosky, S. T., and Scheff, S. W. (1990). Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 27, 457-464.
14. Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., and Gage, F. H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934.
15. Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., and Hyman, B. T. (1997). Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41, 17-24.
16. Graham, D. Y., Opekun, A. R., Willingham, F. F., and Qureshi, W. A. (2005). Visible small-intestinal mucosal injury in chronic NSAID users. Clin. Gastroenterol. Hepatol. 3, 55-59.
17. Green, R. C., Schneider, L. S., Amato, D. A., Beelen, A. P., Wilcock, G., Swabb, E. A., and Zavitz, K. H. (2009). Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557-2564.
18. Hauss-Wegrzyniak, B., Dobrzanski, P., Stoehr, J. D., and Wenk, G. L. (1998). Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain Res. 780, 294-303.
19. Hauss-Wegrzyniak, B., Lynch, M. A., Vraniak, P. D., and Wenk, G. L. (2002). Chronic brain inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant path-granule cell synapses. Exp. Neurol. 176, 336-341.
20. Hauss-Wegrzyniak, B., Vannucchi, M. G., and Wenk, G. L. (2000a). Behavioral and ultrastructural changes induced by chronic neuroinflammation in young rats. Brain Res. 859, 157-166.
21. Hauss-Wegrzyniak, B., Vraniak, P. D., and Wenk, G. L. (2000b). LPS-induced neuroinflammatory effects do not recover with time. Neuroreport 11, 1759-1763.
22. Hayden, K. M., Zandi, P. P., Khachaturian, A. S., Szekely, C. A., Fotuhi, M., Norton, M. C., Tschanz, J. T., Pieper, C. F., Corcoran, C., Lyketsos, C. G., Breitner, J. C., and Welsh-Bohmer, K. A. (2007). Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 69, 275-282.
23. Hee Kang, J., and Grodstein, F. (2003). Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women. Neurology 60, 1591-1597.
24. Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., and Landreth, G. E. (2005). Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453.
25. Hewett, S. J., Silakova, J. M., and Hewett, J. A. (2006). Oral treatment with rofecoxib reduces hippocampal excitotoxic neurodegeneration. J. Pharmacol. Exp. Ther. 319, 1219-1224.
26. Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., and Barnes, C. L. (1984). Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225, 1168-1170.
27. Jantzen, P. T., Connor, K. E., DiCarlo, G., Wenk, G. L., Wallace, J. L., Rojiani, A. M., Coppola, D., Morgan, D., and Gordon, M. N. (2002). Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22, 2246-2254.
28. Johnson, S. C., Schmitz, T. W., Trivedi, M. A., Ries, M. L., Torgerson, B. M., Carlsson, C. M., Asthana, S., Hermann, B. P., and Sager, M. A. (2006). The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J. Neurosci. 26, 6069-6076.
29. Jonker, C., Comijs, H. C., and Smit, J. H. (2003). Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study. Neurobiol. Aging 24, 583-588.
30. Josephs, K. A., Whitwell, J. L., Ahmed, Z., Shiung, M. M., Weigand, S. D., Knopman, D. S., Boeve, B. F., Parisi, J. E., Petersen, R. C., Dickson, D. W., and Jack, C. R. Jr. (2008). Beta-amyloid burden is not associated with rates of brain atrophy. Ann. Neurol. 63, 204-212.
31. Lassmann, H., Fischer, P., and Jellinger, K. (1993). Synaptic pathology of Alzheimer's disease. Ann. N.Y. Acad. Sci. 695, 59-64.
32. Lee, J. W., Lee, Y. K., Yuk, D. Y., Choi, D. Y., Ban, S. B., Oh, K. W., and Hong, J. T. (2008). Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J. Neuroinflammation 5, 37.
33. Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., Tran, T., Ubeda, O., Ashe, K. H., Frautschy, S. A., and Cole, G. M. (2000). Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709-5714.
34. Lim, G. P., Yang, F., Chu, T., Gahtan, E., Ubeda, O., Beech, W., Overmier, J. B., Hsiao-Ashec, K., Frautschy, S. A., and Cole, G. M. (2001). Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22, 983-991.
35. Mackenzie, I. R. (2000). Anti-inflammatory drugs and Alzheimer-type pathology in aging. Neurology 54, 732-734.
36. Mackenzie, I. R., and Munoz, D. G. (1998). Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50, 986-990.
37. Marsland, A. L., Gianaros, P. J., Abramowitch, S. M., Manuck, S. B., and Hariri, A. R. (2008). Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol. Psychiatry 64, 484-490.
38. McGeer, P. L., McGeer, E., Rogers, J., and Sibley, J. (1990). Anti-inflammatory drugs and Alzheimer disease. Lancet 335, 1037.
39. McGeer, P. L., and McGeer, E. G. (1995). The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 21, 195-218.
40. McGeer, P. L., and McGeer, E. G. (2001). Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22, 799-809.
41. McGeer, P. L., Rogers, J., and McGeer, E. G. (2006). Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J. Alzheimer's Dis. 9, 271-276.
42. McKee, A. C., Carreras, I., Hossain, L., Ryu, H., Klein, W. L., Oddo, S., LaFerla, F. M., Jenkins, B. G., Kowall, N. W., and Dedeoglu, A. (2008). Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 1207, 225-236.
43. Mosconi, L., Brys, M., Switalski, R., Mistur, R., Glodzik, L., Pirraglia, E., Tsui, W., De Santi, S., and de Leon, M. J. (2007). Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl. Acad. Sci. U.S.A. 104, 19067-19072.
44. Mueller, S. G., and Weiner, M. W. (2009). Selective effect of age, Apo e4, and Alzheimer's disease on hippocampal subfields. Hippocampus 19, 558-564.
45. Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., and Osborne, D. (1996). Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein. E. N. Engl. J. Med. 334, 752-758.
46. Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B., Alexander, G. E., Klunk, W. E., Mathis, C. A., Price, J. C., Aizenstein, H. J., DeKosky, S. T., and Caselli, R. J. (2009). Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 106, 6820-6825.
47. Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R., Norman, B. A., and Baranak, C. C. (2004). Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62, 66-71.
48. Rogers, J., and Shen, Y. (2000). A perspective on inflammation in Alzheimer's disease. Ann. N.Y. Acad. Sci. 924, 132-135.
49. Rosen, W. G., Terry, R. D., Fuld, P. A., Katzman, R., and Peck, A. (1980). Pathological verification of ischemic score in differentiation of dementias. Ann. Neurol. 7, 486-488.
50. Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., Smith, C., Woodward, M., Merory, J., Tochon-Danguy, H., O'Keefe, G., Klunk, W. E., Mathis, C. A., Price, J. C., Masters, C. L., and Villemagne, V. L. (2007). Imaging beta-amyloid burden in aging and dementia. Neurology 68, 1718-1725.
51. Rozzini, R., Ferrucci, L., Losonczy, K., Havlik, R. J., and Guralnik, J. M. (1996). Protective effect of chronic NSAID use on cognitive decline in older persons. J. Am. Geriatr. Soc. 44, 1025-1029.
52. Small, G. W., Ercoli, L. M., Silverman, D. H., Huang, S. C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., Mazziotta, J. C., Saxena, S., Wu, H. M., Mega, M. S., Cummings, J. L., Saunders, A. M., Pericak-Vance, M. A., Roses, A. D., Barrio, J. R., and Phelps, M. E. (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 97, 6037-6042.
53. Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., Baranak, C. C., and Reines, S. A. (2005). A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30, 1204-1215.
54. Thomas, T., Nadackal, T. G., and Thomas, K. (2001). Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 12, 3263-3267.
55. Trivedi, M. A., Schmitz, T. W., Ries, M. L., Torgerson, B. M., Sager, M. A., Hermann, B. P., Asthana, S., and Johnson, S. C. (2006). Reduced hippocampal activation during episodic encoding in middle-aged individuals at genetic risk of Alzheimer's disease: a cross-sectional study. BMC Med. 4, 1.
56. van Groen, T., and Kadish, I. (2005). Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res. Brain Res. Rev. 48, 370-378.
57. Walther, K., Bendlin, B. B., Glisky, E. L., Trouard, T. P., Lisse, J. R., Posever, J. O., and Ryan, L. (2009). Anti-inflammatory drugs reduce age-related decreases in brain volume in cognitively normal older adults. Neurobiol. Aging. doi:10.1016/j.neurobiolaging.2009.03.006.
58. Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., Kang, D. E., Marquez-Sterling, N., Golde, T. E., and Koo, E. H. (2001). A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216.
59. Willard, L. B., Hauss-Wegrzyniak, B., Danysz, W., and Wenk, G. L. (2000). The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp. Brain Res. 134, 58-65.
60. Willette, A. A., Bendlin, B. B., McLaren, D. G., Canu, E., Kastman, E. K., Kosmatka, K. J., Xu, G., Field, A. S., Alexander, A. L., Colman, R. J., Weindruch, R. H., Coe, C. L., and Johnson, S. C. (2010). Age-related changes in neural volume and microstructure associated with interleukin-6 are ameliorated by a calorie-restricted diet in old rhesus monkeys. Neuroimage 51, 987-994.
61. Xu, G., McLaren, D. G., Ries, M. L., Fitzgerald, M. E., Bendlin, B. B., Rowley, H. A., Sager, M. A., Atwood, C., Asthana, S., and Johnson, S. C. (2009). The influence of parental history of Alzheimer's disease and apolipoprotein E epsilon4 on the BOLD signal during recognition memory. Brain 132, 383-391.
62. Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., and Landreth, G. (2003). Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23, 7504-7509.